1228 — CANbridge Pharmaceuticals Share News
0.000.00%
Last trade - 00:00- HK$1.14bn
- HK$1.08bn
- CNY49.98m
Brief: Canbridge Announces Encouraging Development In Maralixibat/Livmarli In Rare Liver Disease
Brief: Canbridge Pharmaceuticals Says HY Revenue RMB 34.7 Million
Brief: Canbridge Pharmaceuticals Says Unit Entered Into Contractual Arrangements On June 10
Brief: Canbridge Appoints Industry Leader Edward Hu To The Board
Brief: Canbridge Pharmaceuticals Posts FY Revenue RMB31.2 Mln
Brief: Canbridge Pharmaceuticals Got Approval To Treat Patients With PNH In Phase 1B/2 Trial
Drug developer Asymchem Laboratories falls in Hong Kong debut